Sale!

CHRNB2 Gene Epilepsy nocturnal frontal lobe type 3 Genetic Test

4,400 د.إ

-21%

The CHRNB2 gene is associated with a condition known as Epilepsy, nocturnal frontal lobe type 3 (ENFL3), a disorder characterized by seizures that often occur during sleep. These seizures can manifest as sudden arousals from sleep with motor activity, such as bicycling movements of the legs and hyperkinetic complex movements, often accompanied by vocalizations. This condition is linked to mutations in the CHRNB2 gene, which encodes a subunit of the neuronal nicotinic acetylcholine receptor. These receptors are critical for the proper conduction of signals in the brain, and mutations can disrupt normal neuronal activity, leading to seizures.

Genetic testing for mutations in the CHRNB2 gene can be crucial for the diagnosis and management of ENFL3. By identifying specific genetic alterations, healthcare providers can offer more personalized treatment plans and advice on managing the condition. Moreover, genetic testing can help to confirm a diagnosis when the clinical presentation is unclear and can also provide valuable information for family planning.

In the United Arab Emirates, DNA Labs UAE offers a genetic test specifically targeting the CHRNB2 gene to identify mutations associated with Epilepsy, nocturnal frontal lobe type 3. The cost of the test is 4400 AED. This specialized test is performed in a state-of-the-art laboratory setting by experienced professionals, ensuring high-quality, reliable results. By opting for this test, individuals and families affected by or at risk of ENFL3 can gain crucial insights into their condition, paving the way for informed decisions about treatment and management.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test

At DNA Labs UAE, we offer the CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test to help diagnose and understand this specific type of epilepsy. This test is designed to analyze the CHRNB2 gene, which is associated with the development of epilepsy, particularly the nocturnal frontal lobe type 3 (NFLE3) subtype.

Test Details

NFLE3 is a type of epilepsy that causes seizures during sleep. These seizures are often characterized by sudden movements, vocalizations, and confusion upon awakening. By analyzing the CHRNB2 gene through NGS (next-generation sequencing) technology, our genetic test can identify mutations or variations in the gene that may increase the risk of developing NFLE3 or other forms of epilepsy.

Components and Price

The CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test is priced at 4400.0 AED. The test requires a blood sample or extracted DNA, or one drop of blood on an FTA card. The report delivery time is estimated to be 3 to 4 weeks.

Method and Test Type

The test is conducted using NGS technology, which allows for the analysis of multiple genes at once. This comprehensive evaluation of a patient’s genetic profile provides valuable insights into their genetic risk factors for epilepsy and helps inform personalized treatment and management strategies.

Doctor and Test Department

The CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test is recommended for individuals with a family history of epilepsy or those who have experienced seizures during sleep. It is typically ordered by a neurologist and falls under the genetics department.

Pre-Test Information

Prior to undergoing the CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3.

Conclusion

The CHRNB2 Gene Epilepsy Nocturnal Frontal Lobe Type 3 Genetic Test offered by DNA Labs UAE is a valuable tool for diagnosing and understanding this specific type of epilepsy. By analyzing the CHRNB2 gene through NGS technology, we can identify genetic risk factors and provide personalized treatment and management strategies for individuals with NFLE3 or other forms of epilepsy.

Test Name CHRNB2 Gene Epilepsy nocturnal frontal lobe type 3 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CHRNB2 Gene Epilepsy, nocturnal frontal lobe type 3 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CHRNB2 Gene Epilepsy, nocturnal frontal lobe type 3
Test Details

The CHRNB2 gene is associated with the development of epilepsy, particularly the nocturnal frontal lobe type 3 (NFLE3) subtype. NFLE3 is a type of epilepsy that causes seizures during sleep, often characterized by sudden movements, vocalizations, and confusion upon awakening.

NGS (next-generation sequencing) genetic testing is a type of genetic testing that can analyze multiple genes at once, providing a more comprehensive evaluation of a patient’s genetic profile. NGS testing for the CHRNB2 gene can help identify mutations or variations in the gene that may increase the risk of developing NFLE3 or other forms of epilepsy.

Individuals with a family history of epilepsy or who have experienced seizures during sleep may benefit from NGS genetic testing to identify potential genetic risk factors and inform personalized treatment and management strategies.